表紙
市場調查報告書

全球病毒載體製造市場與技術

Global Viral Vector Manufacturing Markets and Technologies Through 2022

出版商 BCC Research 商品編碼 718321
出版日期 內容資訊 英文 255 Pages
訂單完成後即時交付
價格
Back to Top
全球病毒載體製造市場與技術 Global Viral Vector Manufacturing Markets and Technologies Through 2022
出版日期: 2018年10月04日內容資訊: 英文 255 Pages
簡介

全球病毒載體製造市場,預計從2017年的2290萬美元,到2022年達約5120萬美元。預計市場2017年∼2022年以17.5%的年複合成長率成長。

本報告提供全球病毒載體製造市場相關調查分析,市場概要,市場趨勢分析與預測,技術創新,市場動態,開發中產品,主要企業簡介等系統性資訊。

第1章 簡介

第2章 摘要和亮點

第3章 市場與技術的背景

  • 進化與轉移
  • 市場潛在性
  • 市場區隔
  • 各地區分析

第4章 推動市場要素

  • 病毒載體的臨床試驗增加
  • 基因治療的候補藥增加
  • 基因治療為基礎的研究開發投資劇增
  • 遺傳性疾病、慢性疾病的盛行率增加

第5章 市場明細:各類型

  • 概要
  • 腺病毒載體
  • 反轉錄病毒媒介
  • 慢病毒媒介
  • 腺相關病毒載體
  • 巨細胞病毒
  • 痘病毒
  • 其他

第6章 市場明細:各疾病適應症

  • 概要
  • 人疾病適應
  • 動物疾病適應

第7章 市場明細:各適應類型

  • 概要
  • 多效價病毒載體疫苗
  • 多重抗藥性病毒載體疫苗

第8章 市場明細:各地區

  • 北美
  • 歐洲
  • 亞太地區
  • 其他

第9章 病毒載體製造產業結構

  • 病毒載體製造
  • 腺病毒
  • 慢病毒媒介
  • 腺相關媒介 (AAV)
  • 製造商購買標準
  • 技術創新
  • 競爭情形

第10章 專利分析

  • 美國的專利分析
  • 歐洲的專利分析
  • 日本的專利分析

第11章 企業簡介

關於BCC Research

目錄
Product Code: PHM172A

Report Highlights:

The global market for viral vector vaccine manufacturing is expected to increase from $22.9 million in 2017 to nearly $51.2 million in 2022 at a compound annual growth rate (CAGR) of 17.5% for 2017-2022.

The market for pox viral vector vaccine manufacturing is expected from $6.6 million in 2017 to $15.1 million in 2022 at a compound annual growth rate (CAGR) of 17.9% for 2017-2022.

The market for adenoviral vector vaccine manufacturing is expected from nearly $4.7 million in 2017 to $10.8 million in 2022 at a compound annual growth rate (CAGR) of 18.2% for 2017-2022.

Report Scope:

The scope of this report is broad and covers various types of products available, ongoing research and development in the viral vector vaccine manufacturing market, and potential application sectors across various industries. The viral vector vaccine manufacturing market is broken down by types, application and diseases. Revenue forecasts from 2017 to 2022 are given for each product type, application and diseases with estimated valued derived from the revenue of manufacturers' total revenues.

The report also includes a discussion of the major players across each regional viral vector vaccine manufacturing market. Further, it explains the major drivers and regional dynamics of the global viral vector vaccine manufacturing market and current trends within the industry.

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors in the global viral vector vaccine manufacturing market.

Report Includes:

  • 145 data tables and 57 additional tables
  • A detailed overview and industry analysis of global viral vector manufacturing market
  • Analyses of global market trends, with data from 2017, estimates for 2018, and projections of compound annual growth rates (CAGRs) through 2023
  • Information on major drivers and regional dynamics of the global viral vector vaccine manufacturing market and current trends within the industry
  • Insight into pipeline products that are manufactured using viral vector tools and technology, and a relevant patent analysis
  • Company profiles of major market players including Advanced Bioscience Laboratories Inc., Boehringer Ingelheim Gmbh, Brammer Bio Llc, Creative Biogene, GE Healthcare, Pfizer Inc., Sanofi SA, and Spark Therapeutics Inc.

Table of Contents

Chapter 1: INTRODUCTION

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • BCC Custom Research
  • Related Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Market and Technology Background

  • Evolution and Transition
  • Market Potential
    • WHO
    • U.S.
    • European Union
    • Australia
    • Japan
    • India
    • China
  • Market Segmentation
    • Segmentation by Type
    • Segmentation by Application
    • Segmentation by Disease
  • Regional Analysis
    • North America
    • Europe
    • Asia-Pacific
    • ROW

Chapter 4: Market Drivers

  • Rising Number of Clinical Trials in Viral Vectors
  • Growing Number of Gene Therapy Candidates
  • Surging Investment in Gene-Therapy-Based R&D Activities
  • Increasing Prevalence of Genetic Disorders and Chronic Diseases

Chapter 5: Market Breakdown by Type

  • Overview
  • Adenoviral Vectors
  • Retroviral Vectors
  • Lentiviral Vectors
  • Adeno-associated Viral Vectors
  • Cytomegalovirus
  • Pox Virus
  • Other Viral Vectors

Chapter 6: Market Breakdown by Disease Application

  • Overview
  • Human Disease Applications
    • Overview
    • Hepatitis
    • Cancer
    • Influenza
    • HIV
    • Tuberculosis
    • Malaria
    • Others
  • Veterinary Disease Applications
    • Avian Influenza
    • Marek's Disease
    • Infectious Bronchitis
    • PPR Disease
    • Others (Rabies, FMD, Swine Influenza, Equine Influenza, Newcastle Disease, etc.)

Chapter 7: Market Breakdown by Application Type

  • Overview
  • Multivalent Viral Vector Vaccines
  • Multipathogen Viral Vector Vaccines

Chapter 8: Market Breakdown by Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World (ROW)
    • Latin America
    • Middle East and Africa

Chapter 9: Viral Vector Manufacturing Industry Structure

  • Viral Vector Manufacturing Supply Chain
  • Common Steps Followed in Small-Scale Manufacturing of Adenovirus
    • Step 1: Cell Lysis and Genomic DNA Breakdown
    • Step 2: Clari?cation
    • Step 3: Concentration
    • Steps 4 and 5: Anion Exchange and Gel Filtration
    • Step 6: Membrane Filtration
  • Companies Involved in Developing Lentiviral Vector Candidates
  • Companies Involved in Developing Adeno-associated Vector (AAV) Candidates
  • Manufacturer Purchasing Criteria
  • Innovation within the Viral Vector Vaccine Manufacturing Industry
  • Competitive Landscape
    • Expansions
    • Collaborations
    • Investments
    • Acquisitions

Chapter 10: Patent Analysis

  • U.S. Patent Analysis
  • European Patent Analysis
  • Japanese Patent Analysis

Chapter 11: Company Profiles

  • ADVANCED BIOSCIENCE LABORATORIES, INC.
  • ADVANCED BIOTHERAPEUTICS CONSULTING
  • APPLIED VIROMICS
  • BATAVIA BIOSCIENCES
  • BENITEC BIOPHARMA
  • BIOGEN IDEC (NOW BIOGEN, INC.)
  • BIOVIAN
  • BOEHRINGER INGELHEIM GMBH
  • BRAMMER BIO
  • CELL AND GENE THERAPY CATAPULT
  • CEVA CORPORATE
  • COBRA BIOLOGICS (SUBSIDIARY OF RECIP AB)
  • CREATIVE BIOGENE
  • GE HEALTHCARE
  • GENEDETECT
  • GENVEC INC. (SUBSIDIARY OF INTREXON CORP.)
  • ID PHARMA CO. LTD.
  • JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
  • LONZA
  • MERCK MILLIPORE
  • MILTENYI BIOTEC
  • MOLMED SPA
  • PARAGON BIOSERVICES INC.
  • PFIZER INC.
  • SANOFI
  • SEMENTIS
  • SPARK THERAPEUTICS INC.
  • SYNPROMICS
  • VALNEVA
  • VECTOR BIOLABS
  • VIGENE BIOSCIENCES INC.
  • VIROVEK

List of Tables

  • Summary Table: Global Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 1: Characteristics of Potential Viral Vaccine Vectors
    • Table 2: Advantages and Disadvantages of Major Viral Vectors
    • Table 3: Global Market Shares of Viral Vector Vaccine Manufacturing, by Type, 2016 vs. 2022
    • Table 4: Global Market Shares of Viral Vector Vaccine Manufacturing, by Application Type, 2016 and 2022
    • Table 5: Global Market Shares of Viral Vector Vaccine Manufacturing, by Disease Segment, 2016 and 2022
    • Table 6: Vaccine Designs and Strategies for Their Utility Against HIV
    • Table 7: Global Market Shares of Viral Vector Vaccine Manufacturing, by Region, 2016 and 2022
    • Table 8: Driver Impact Analysis for Global Viral Vector Vaccine Manufacturing Market
    • Table 9: List of Clinical Trials with Their Conditions and Interventions
    • Table 10: Distribution of Diseases Targeted by Prophylactic Gene-Based Vaccines
    • Table 11: Properties of Various Viral Vectors and Their Application in Gene Therapy
    • Table 12: Global Incidence of Chronic Diseases, 2005-2030
    • Table 13: Global Prevalence of Colon Cancer, by Age Group, 2016
    • Table 14: Global Incidence of HIV Disease, by Region, 2016
    • Table 15: Various Types of Viral Vectors Used in Gene Therapy and Their Advantages
    • Table 16: Characteristics of Key Viral Vectors
    • Table 17: Global Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 18: Global Adenoviral Vector Vaccine Manufacturing Market, by Region, Through 2022
    • Table 19: Global Retroviral Vector Vaccine Manufacturing Market, by Region, Through 2022
    • Table 20: Advantages and Disadvantages of Retroviral Vectors
    • Table 21: List of Retroviral Vector Vaccines under Development as of March 2018
    • Table 22: Components of HIV Provirus
    • Table 23: Clinical Trials Deploying Lentiviral Vectors for Modification of Hematopoietic Stem Cells by Phase
    • Table 24: Global Lentiviral Vector Vaccine Manufacturing Market, by Region, Through 2022
    • Table 25: Second- versus Third-Generation Lentiviral Systems
    • Table 26: Selected AAV Vectors with Their Tropisms and Receptors
    • Table 27: Global Adeno-associated Vector Vaccine Manufacturing Market, by Region, Through 2022
    • Table 28: Global Cytomegalovirus Vector Vaccine Manufacturing Market, by Region, Through 2022
    • Table 29: Human Cytomegalovirus Vaccine Candidates in Different Stages of Preclinical and Clinical Development
    • Table 30: Licensed Fowl Pox Viral-Vectored Veterinary Vaccines
    • Table 31: Global Pox Virus Vector Vaccine Manufacturing Market, by Region, Through 2022
    • Table 32: Benefits and Drawbacks of HSV Viral Vectors
    • Table 33: Global Other Viral Vector Vaccines Manufacturing Market, by Region, Through 2022
    • Table 34: HSV Proposed Vaccines and Their Characteristics
    • Table 35: Global Viral Vector Vaccine Manufacturing Market, by Disease Segment, Through 2022
    • Table 36: Licensed Viral and Bacterial Vaccines for Use in Humans
    • Table 37: Global Viral Vector Vaccine Manufacturing Market, by Human Disease Application, Through 2022
    • Table 38: Global Viral Vector Manufacturing Market in Human Disease, by Region, Through 2022
    • Table 39: Pricing in Gavi Countries: Product-Specific Commitments
    • Table 40: Estimated New Cases of HAV
    • Table 41: Number of Death Certificates Listing HAV, HBC and HCV as a Cause of Death, 2015 and 2016
    • Table 42: Prevalence of HBV Infection (HBSAG) in the General Population, by WHO Region, 2015
    • Table 43: Leading Sites of Estimated New Cancer Cases in U.S, 2017
    • Table 44: Virus-Vectored Experimental Influenza Vaccines
    • Table 45: Some of the Delivery Vectors Evaluated in Clinical Studies for HIV Vaccines
    • Table 46: People Living with HIV, by Region, 2016
    • Table 47: Tuberculosis Viral Vector Vaccine Candidates
    • Table 48: Ongoing Preclinical Development and Clinical Trials on Malaria Vaccines
    • Table 49: Top 10 Priority Initiatives for Malaria Vaccine Development According to the Malaria Vaccine Technology Roadmap
    • Table 50: Ongoing Clinical Trials of Vector Vaccines against EVD, As of 2017
    • Table 51: EVD Cases and Death, by Country
    • Table 52: Zika Virus Vaccine Development and Ongoing Clinical Trials
    • Table 53: Licensed Viral-Vectored Veterinary Vaccines
    • Table 54: Global Estimates of the Growth in Demand for Meat, 2010-2030
    • Table 55: Global Viral Vector Vaccine Manufacturing Market, by Veterinary Disease Application, Through 2022
    • Table 56: Global Viral Vector Vaccine Manufacturing Market for Veterinary Disease Application, by Region, Through 2022
    • Table 57: Avian Influenza Vaccines
    • Table 58: Global Estimates of Poultry Production
    • Table 59: Marek's Disease Vaccines
    • Table 60: Grants Supporting the Development of Novel Recombinant Adenovirus-Based Vaccine Candidates for Respiratory Diseases in Chickens
    • Table 61: Global Viral Vector Vaccine Manufacturing Market, by Application, Through 2022
    • Table 62: Comparison of the Viral Vectors Discussed Based on Specific Vector Characteristics
    • Table 63: Global Multivalent Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
    • Table 64: Global Incidence of HIV Disease, by Region, 2015 and 2016
    • Table 65: Global Incidence of TB, by Region, 2016
    • Table 66: Global Multipathogen Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
    • Table 67: Overview of Multivalent/Polyvalent and Multipathogen/Multidisease Viral Vector Vaccine Candidates, by Vector
    • Table 68: Global Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
    • Table 69: North American Viral Vector Vaccine Manufacturing Market, by Country, Through 2022
    • Table 70: North American Viral Vector Manufacturing Market, by Type, Through 2022
    • Table 71: Cancer Research Funding in the U.S., 2015 and 2016
    • Table 72: North American Viral Vector Manufacturing Market, by Application Type, Through 2022
    • Table 73: U.S. Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 74: North American Viral Vector Manufacturing Market, by Disease Segment, Through 2022
    • Table 75: NIH Funding for CRISPR-Related Research, 2006-2016
    • Table 76: North American Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
    • Table 77: New HIV Diagnoses in the U.S., by Age Group, 2016
    • Table 78: Viral Vector Vaccines in Development in U.S.
    • Table 79: Canadian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 80: North American Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
    • Table 81: Confirmed Influenza Cases in Mexico, 2012-2016
    • Table 82: Mexican Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 83: European Viral Vector Vaccine Manufacturing Market, by Country, Through 2022
    • Table 84: Losses Due to HPAI Outbreaks in Domestic Birds, by Region, January 2013-January 2018
    • Table 85: Recent Impact of HPAI in Domestic Birds, by Region, February 2018
    • Table 86: German Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 87: European Viral Vector Manufacturing Market, by Type, Through 2022
    • Table 88: U.K. Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 89: European Viral Vector Manufacturing Market, by Application Type, Through 2022
    • Table 90: HIV/AIDS Statistics in the U.K., 2015
    • Table 91: People Living with HIV (All Ages) in France, 2000-2016
    • Table 92: French Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 93: Distribution of the Leading Causes of Death in Women in France, 2017
    • Table 94: Distribution of the Leading Causes of Death in Men in France, 2017
    • Table 95: European Viral Vector Manufacturing Market, by Disease Segment, Through 2022
    • Table 96: European Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
    • Table 97: HPAI Outbreaks in Poultry and Wild Bird Cases in the E.U., October 2016 - July 2017
    • Table 98: European Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
    • Table 99: Spanish Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 100: Number of People in Spain Infected with HIV, by Age, 2000-2016
    • Table 101: Italian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 102: Italian Poultry Meat Production, 2016
    • Table 103: Rest of Europe Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 104: Number of People Infected with HIV in Select Countries in the Rest of Europe Region, 2000-2016
    • Table 105: Asia-Pacific Viral Vector Vaccine Manufacturing Market, by Country, Through 2022
    • Table 106: Asia-Pacific Viral Vector Manufacturing Market, by Type, Through 2022
    • Table 107: Chinese Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 108: Asia-Pacific Viral Vector Manufacturing Market, by Application Type, Through 2022
    • Table 109: Ongoing Preclinical and Clinical Trials of HIV/AIDS Vaccine in China
    • Table 110: Asia-Pacific Viral Vector Manufacturing Market, by Disease Segment, Through 2022
    • Table 111: Confirmed Cases of Human Infection with Avian Influenza in China, 2013 and 2016
    • Table 112: Asia-Pacific Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
    • Table 113: Indian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 114: Prevalence of Tuberculosis Cases in India, 2016
    • Table 115: Asia-Pacific Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
    • Table 116: Ongoing Clinical Trials Related to HIV Vaccines in India
    • Table 117: Japanese Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 118: Reported Cumulative Number of HIV Cases in Japan, 2012 and 2016
    • Table 119: Australian Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 120: Various Viral Vaccine Vectors Used in AIDS Vaccine Development
    • Table 121: Number of Newly Diagnosed Cases of HIV Infection in Australia, 2012-2016
    • Table 122: South Korean Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 123: HPAI Outbreaks in South Korea, 2003-2017
    • Table 124: Vaccine Strains for Immunization of Chickens against H5N1 HPAIVS
    • Table 125: Distribution of Causes of Death in South Korea, 2016
    • Table 126: Rest of APAC Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 127: Leading Causes of Deaths in Singapore, 2014-2016
    • Table 128: Mortality by Sex and Cause of Death, 2016
    • Table 129: HIV/AIDS Statistics for Thailand, 2016
    • Table 130: Ongoing Clinical Trials for Preventive HIV Vaccine Candidates in Thailand
    • Table 131: Estimated Worldwide Rates of Skin Cancer per Capita
    • Table 132: Newly Diagnosed HIV Cases in the Philippines, by Age Group, 2016
    • Table 133: Number of Newly Diagnosed HIV Cases per Day in the Philippines, 2008-2017
    • Table 134: ROW Viral Vector Vaccine Manufacturing Market, by Region, Through 2022
    • Table 135: ROW Viral Vector Manufacturing Market, by Type, Through 2022
    • Table 136: Latin American Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 137: Poultry Consumption across ROW Countries, 2017
    • Table 138: ROW Viral Vector Manufacturing Market by Application Type Through 2022
    • Table 139: Top 10 Causes of Deaths in Cuba and Percentage Change from 2005 to 2016
    • Table 140: Middle East and African Viral Vector Vaccine Manufacturing Market, by Type, Through 2022
    • Table 141: ROW Viral Vector Manufacturing Market, by Disease Segment, 2017-2022
    • Table 142: Characteristics of the Priority Diseases Identified in the WHO R&D Blueprint, Revised, 2017
    • Table 143: ROW Viral Vector Manufacturing Market, by Human Disease Application, Through 2022
    • Table 144: ROW Viral Vector Manufacturing Market, by Veterinary Disease Application, Through 2022
    • Table 145: Viral Vector Overview
    • Table 146: Related Impurities to be Eliminated, by Downstream Processing
    • Table 147: Viral Vector Manufacturing Suppliers
    • Table 148: List of Some of the Viral Vector Producers
    • Table 149: List of Company Expansion
    • Table 150: List of Collaborations
    • Table 151: List of Investments
    • Table 152: List of Acquisitions
    • Table 153: U.S. Viral Vector Vaccine Manufacturing Patents, 2015-May 2018
    • Table 154: European Viral Vector Vaccine Manufacturing Patents, 2015-May 2018
    • Table 155: Japanese Viral Vector Vaccine Manufacturing Patents, 2015-May 2018
    • Table 156: Advanced BioScience Laboratories Product Portfolio
    • Table 157: Advanced BioScience Laboratories Recent Developments, 2015-April 2018
    • Table 158: Advanced Biotherapeutics Consulting Product Portfolio
    • Table 159: Applied Viromics Product Portfolio
    • Table 160: Batavia Biosciences Product Portfolio
    • Table 161: Batavia Bioscience Recent Developments, 2015-April 2018
    • Table 162: Benitec Biopharma Product Portfolio
    • Table 163: Biogen Product Portfolio
    • Table 164: Biogen Recent Developments, 2015-April 2018
    • Table 165: Biovian Product Portfolio
    • Table 166: Boehringer Ingelheim Product Portfolio
    • Table 167: Brammer Bio Product Portfolio
    • Table 168: Brammer Bio Recent Developments, 2015-April 2018
    • Table 169: Cell and Gene Therapy Catapult Product Portfolio
    • Table 170: Cell and Gene Therapy Catapult Recent Developments, 2015 - April 2018
    • Table 171: Ceva Product Portfolio
    • Table 172: Cobra Biologics Product Portfolio
    • Table 173: Cobra Biologics Recent Developments, 2015 - April 2018
    • Table 174: Creative Biogene Product Portfolio
    • Table 175: GE Healthcare Product Portfolio
    • Table 176: GeneDetect Product Portfolio
    • Table 177: GenVec Product Portfolio
    • Table 178: ID Pharma Product Portfolio
    • Table 179: Janssen Product Portfolio
    • Table 180: Janssen Recent Developments, 2015 - April 2018
    • Table 181: Lonza Group Product Portfolio
    • Table 182: Lonza Group Recent Developments, 2015 - April 2018
    • Table 183: Merck Millipore Product Portfolio
    • Table 184: Merck Millipore Recent Developments, 2015 - April 2018
    • Table 185: Miltenyi Biotec Product Portfolio
    • Table 186: MolMed Product Portfolio
    • Table 187: Paragon Bioservices Product Portfolio
    • Table 188: Paragon Bioservices Recent Developments, 2015 - April 2018
    • Table 189: Pfizer Product Portfolio
    • Table 190: Pfizer Recent Developments, 2015 - April 2018
    • Table 191: Sanofi Product Portfolio
    • Table 192: Sementis Product Portfolio
    • Table 193: Spark Therapeutics Product Portfolio
    • Table 194: Spark Therapeutics Recent Developments, 2015 - April 2018
    • Table 195: Synpromics Product Portfolio
    • Table 196: Synpromics Recent Developments, 2015 - April 2018
    • Table 197: Valneva Product Portfolio
    • Table 198: Vector Biolabs Product Portfolio
    • Table 199: Vigene Biosciences Product Portfolio
    • Table 200: Vigene Biosciences Recent Developments, 2015 - April 2018
    • Table 201: Virovek Product Portfolio

List of Figures

  • Summary Figure: Global Viral Vector Vaccine Manufacturing Market, by Type, 2017-2022
    • Figure 1: Notable Vaccine Advancements
    • Figure 2: Vaccine Research Cycle
    • Figure 3: WHO Mandatory Steps for Vaccine Approval
    • Figure 4: FDA Stages of Vaccine Review and Regulation
    • Figure 5: EMA Stages of Vaccine Review and Regulation
    • Figure 6: MHLW Stages of Vaccine Review and Regulation
    • Figure 7: Vaccine Approval Process in India
    • Figure 8: Life Cycle of Virus in Cells
    • Figure 9: Key Properties of Viral Vector
    • Figure 10: Global Market Shares of Viral Vector Vaccine Manufacturing, by Type, 2016 and 2022
    • Figure 11: Working of an Ad-Vector Vaccine
    • Figure 12: Role of CMV in Immunosenesce of Humans
    • Figure 13: Global Market Shares of Viral Vector Vaccine Manufacturing, by Application Type, 2016 - 2022
    • Figure 14: Global Market Shares of Viral Vector Vaccine Manufacturing, by Disease Segment, 2016 and 2022
    • Figure 15: Global Market Shares of Viral Vector Vaccine Manufacturing, by Region, 2016 and 2022
    • Figure 16: Distribution of Diseases Targeted by Prophylactic Gene-Based Vaccines
    • Figure 17: Global Incidence of Chronic Diseases 2005-2030
    • Figure 18: Global Prevalence of Colon Cancer, by Age Group, 2016
    • Figure 19: Global Incidence of HIV Disease, by Region, 2016
    • Figure 20: Structure of Third-Generation Lentiviral Vectors
    • Figure 21: Prevalence of HBV Infection (HBSAG) in the General Population, by WHO Region, 2015
    • Figure 22: People Living with HIV, by Region, 2016
    • Figure 23: EVD Cases and Death, by Country
    • Figure 24: Global Estimates of the Growth in Demand for Meat, 2010-2030
    • Figure 25: Global Shares of Demand for Meat, 2010 and 2030
    • Figure 26: Global Estimates of Poultry Production
    • Figure 27: Schematic Overview of Multipathogen/Multidisease and Multivalent/Polyvalent Viral Vector Vaccines
    • Figure 28: Global Incidence of HIV Disease, by Region, 2015 and 2016
    • Figure 29: Comparative Analysis of Regional Market Shares, 2016 vs. 2022
    • Figure 30: New HIV Diagnoses in the U.S., by Age Group, 2016
    • Figure 31: Confirmed Influenza Cases in Mexico, 2012-2016
    • Figure 32: Losses Due to HPAI Outbreaks in Domestic Birds, by Region, January 2013-January 2018
    • Figure 33: People Living with HIV (All Ages) in France, 2000-2016
    • Figure 34: Distribution of the Leading Causes of Death in Women in France, 2017
    • Figure 35: Distribution of the Leading Causes of Death in Men in France, 2017
    • Figure 36: Number of People in Spain Infected with HIV, by Age, 2000-2016
    • Figure 37: Italian Poultry Meat Production, 2016
    • Figure 38: Number of People Infected with HIV in Select Countries in the Rest of Europe Region, 2000-2016
    • Figure 39: Confirmed Human Infection with Avian Influenza in China, 2013 and 2016
    • Figure 40: Reported Cumulative Number of HIV Cases in Japan, 2012 and 2016
    • Figure 41: Number of Newly Diagnosed Cases of HIV Infection in Australia, 2012-2016
    • Figure 42: Distribution of Causes of Death in South Korea, 2016
    • Figure 43: Estimated Worldwide Rates of Skin Cancer per Capita
    • Figure 44: Newly Diagnosed HIV Cases in the Philippines, by Age Group, 2016
    • Figure 45: Number of Newly Diagnosed HIV Cases per Day in the Philippines, 2008-2017
    • Figure 46: Poultry Consumption Across ROW Countries, 2017
    • Figure 47: Features of Vectors
    • Figure 48: Key Properties of Viral Vectors
    • Figure 49: Common Viral-Vector Manufacturing Process
    • Figure 50: Viral Vector Manufacturing Process
    • Figure 51: Adenovirus Manufacturing Process
    • Figure 52: Viral-Vector Vaccine Manufacturing Industry
    • Figure 53: Level of Impact of Manufacturer Purchasing Criteria, 2018-2022
    • Figure 54: Shares of Competitive Landscape, 2015-2018
Back to Top